SO-008

Ramucirumab plus merestinib in previously treated metastatic colorectal cancer: safety, pharmacokinetic, and preliminary efficacy findings from a Phase 1 study

Authors

 

SalehM 1
CassierP 2
EberstL 2
NaikG 3
IIV Morris 4
PantS 5
TerretC 2
GaoL 6
LongA 7
MaoH 7
McNeelyS 7
CarlesiR 8
FuS 9
Georgia Cancer Specialists, Atlanta, USA

Centre Léon Bérard, Department of Medical Oncology, Lyon, France O’Neal Comprehensive Cancer Center of University of Alabama at Birmingham, Birmingham, Alabama, USA The University of Texas MD Anderson Cancer Center, Houston, Texas, USA MD Anderson Cancer Center, Houston, Texas, USA Eli Lilly and Company, Bridgewater, New Jersey, USA Eli Lilly and Company, Indianapolis, Indiana, USA Eli Lilly and Company, Sesto Fiorentino, Italy The University of Texas M D Anderson Cancer Center, Houston, Texas, USA

 

Stay in the know.
OncNet Newsletter